X-linked retinoschisis (XLRS)
X-linked retinoschisis (XLRS) is an inherited condition that causes early loss of mainly central vision in males.
Search
Search results
Look Forward – Spring 2025 – Issue 185
This edition of Look Forward includes the very latest news about an experimental therapy by Retina UK funded researchers, an article about one of our PhD students, a calendar of events in 2025, the usual research news round-up and lots more. Please take the time to complete our Sight Loss Survey, enclosed with this edition. You can find out more about the Survey.
Artificial vision
There are about 125 million rod and cone cells within the retina that act as the eye's light receptors.
Cell-ebrating the dosing of patients with jCell in a phase 2 clinical trial for RP
The latest research news from Retina UK.
Funding paves the way for achromatopsia
A research project funded by Retina UK helped pave the way to a new gene therapy that has recently produced encouraging results in two young people with achromatopsia, a condition that causes complete colour-blindness and poor overall vision from birth.
Drugs for cancer and alcoholism show promise for RP
With all the interest in exciting gene and cell therapies for inherited sight loss, it’s easy to forget that more traditional drugs can also hold promise.
Flipping the switch on RP: SparingVision doses patients in their first in-human clinical trial for SPVN20
The latest research news from Retina UK.
Research grant awards worth £870K announced
Retina UK is delighted to announce that it has awarded three new research grants worth more than £870,000.
Research news roundup – innovation in 2022
Despite the knock-on effects of the pandemic, there’s been a lot going on this year in the world of research! Here are snapshots of a few stories that have appeared in the Research News section of our website in 2022.